ReviewFrontiers in oncology2026
Electrospun nanofibers for gastric cancer: local therapeutics, biomimetic models, and diagnostic interfaces.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrospun nanofibers have emerged as a versatile local-regional platform for gastric cancer, particularly for postoperative recurrence control and peritoneal metastasis, where systemic therapies often fail to achieve sufficient and durable intraperitoneal exposure. Owing to their high surface area, interconnected porosity, and engineerable architecture, electrospun membranes enable programmable local pharmacokinetics and tunable cell-material interactions by regulating fiber diameter, pore connectivity, and alignment. Advanced designs, including coaxial, Janus, multilayer, gradient, and porous fibers, further expand the therapeutic window by separating drug compatibility from release behavior and supporting sequential or compartmentalized delivery. In perioperative settings, electrospun patches can function as locoregional depots to suppress microscopic residual disease while simultaneously facilitating infection control and tissue repair. For peritoneal metastasis, electrospun membranes can sustain intraperitoneal drug exposure and incorporate microenvironment-responsive sensitization strategies targeting hypoxia, redox adaptation, and ferroptosis resistance. Beyond therapy, electrospun scaffolds provide biomimetic gastric cancer models that better recapitulate diffusion barriers, metabolic gradients, and mechanobiological cues, improving the translational relevance of drug-response evaluation. Nanofiber-based interfaces also support longitudinal monitoring by enhancing the capture and analysis of circulating tumor cells and other low-abundance biomarkers. Finally, we highlight key translational considerations, including quality-by-design, critical quality attributes, sterilization robustness, and scalable manufacturing, to accelerate clinical adoption of electrospun products for gastric cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.